Minneapolis Clinic of Neurology

Golden Valley, Minnesota 55442

0 studies enrolling now · 20 studies all time

What they study most

Brain Infarction, Cardiovascular Disease, Cerebral Ischemia, Drug Resistant Partial Onset Seizure, Epilepsy, Epilepsy With Partial On-set Seizures, Episodic Migraine, Migraine, With or Without Aura, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Partial Onset Seizures

Studies at this site

• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis — Paused
• Cenobamate Open-Label Extension Study for YKP3089C025 — Completed
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis — Running, not enrolling
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures — Stopped early
• Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension — Completed
• Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) — Completed
• Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis — Completed
• A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures — Completed
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® — Completed
• Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) — Completed
• Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke — Stopped early